The MIT Quant, and head of AlphaSimplex Group proposes a fund to invest in biotechnology cures for cancer.

The source article is here and Mr. Lo's proposal is here.

Born in Hong Kong and raised in New York City, Lo lost his mother last year to lung cancer. He, like many people, also has watched friends and colleagues struggle with the disease in its various forms.

As an economist, he said, “I felt pretty helpless.’’

So he decided to focus on an area where he could have an impact: funding sources for cancer research.

In his Nature Biotechnology paper, Lo calls the current business model for drug research and development flawed, noting that the number of drug applications per dollar of spending is declining, and pharmaceutical stocks as a group have fared poorly over the past decade.

Under Lo’s proposal, the oncology fund could pour money into more speculative, early-stage research in exchange for a percentage of future royalties or proceeds from sales of intellectual property. A successful cancer drug can generate $2 billion a year in revenue, he said.

The excellent blog Six Figure investing did a profile of one my favorite ETN's, the Barclays S&P Veqtor ETN. We use this product in several of our strategies at Schenley Park Advisors. You may find the profile here.

I rarely mention specific securities on this blog, so below the chart is our disclaimer:



















Schenley Park Capital Management, LLC ("SPCM") is a Registered Investment Advisor ("RIA"), registered in the Commonwealth of Pennsylvania. SPCM provides asset management and related services for clients nationally. SPCM will file and maintain all applicable licenses as required by the state securities boards and/or the Securities and Exchange Commission ("SEC"), as applicable. SPCM renders individualized responses to persons in a particular state only after complying with the state's regulatory requirements, or pursuant to an applicable state exemption or exclusion.

This web site is intended to provide general information about SPCM. It is not intended to offer investment advice. Information regarding investment products and services are provided solely to read about our investment philosophy, our strategies and to be able to contact us for further information.

Market data, articles and other content on this web site are based on generally-available information and are believed to be reliable. SPCM does not guarantee the accuracy of the information contained in this web site. The information is of a general nature and should not be construed as investment advice.

Here at HedgeRoll, we have followed the "Twitter Hedge Fund" from Derwent Capital Markets since its launch.

However it seems to have shut down, and is now offering its signals to day traders.

Previous HedgeRoll articles:
Twitter Hedge Fund Manager Interview
Twitter Hedge Fund: Overwhelming Demand
Hedge Fund to trade based on Twitter Signals